Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.

Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity until July 31.

“Illumina’s technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry,” Illumina's board chair, Stephen P. MacMillan, said in a statement. “We are confident Illumina can continue to execute on its goals, while we conduct and complete a CEO search process.”

The company, based in San Diego, said the board is looking at internal and external candidates.

The resignation comes as Illumina has been locked in a monthslong heated battle with activist investor Carl Icahn, over its $7.1 billion acquisition of cancer test maker Grail that has faced regulatory hurdles. Icahn had urged shareholders to vote out its chairman, John Thompson, and deSouza. Company shareholders voted out Thompson in late May.

Share:
More In Business
How Landlines Lost the American Public
During AT&T's widespread outage Thursday, landline phones were a working alternative — which most of the U.S. does not have. Over half of Americans are estimated to have ditched landlines altogether.
Ending the Black Maternal Morbidity Crisis
Jade Kearney Dube, Founder & CEO of She Matters talks the Symptom Tracker app, cultural competency for healthcare providers, and being a Black woman CEO looking for funding.
The Future of Bit Mining
Ahead of April’s planned BitCoin halving, Bitfarms CEO Geoff Morphy shares why he thinks the crypto rally will continue, plus why you’ll see a broader adoption of clean energy for mining.
Load More